| A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value BA Walker, PE Leone, L Chiecchio, NJ Dickens, MW Jenner, KD Boyd, ... Blood, The Journal of the American Society of Hematology 116 (15), e56-e65, 2010 | 469 | 2010 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 380 | 2019 |
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Oncology 20 (1), 57-73, 2019 | 366 | 2019 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 261 | 2019 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 251 | 2018 |
| Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma BA Walker, PE Leone, MW Jenner, C Li, D Gonzalez, DC Johnson, ... Blood 108 (5), 1733-1743, 2006 | 231 | 2006 |
| Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple … MW Jenner, PE Leone, BA Walker, FM Ross, DC Johnson, D Gonzalez, ... Blood, The Journal of the American Society of Hematology 110 (9), 3291-3300, 2007 | 180 | 2007 |
| Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome NJ Dickens, BA Walker, PE Leone, DC Johnson, JL Brito, A Zeisig, ... Clinical Cancer Research 16 (6), 1856-1864, 2010 | 166 | 2010 |
| MMSET deregulation affects cell cycle progression and adhesion regulons in t (4; 14) myeloma plasma cells JLR Brito, B Walker, M Jenner, NJ Dickens, NJM Brown, FM Ross, ... haematologica 94 (1), 78, 2008 | 147 | 2008 |
| A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) R Hájek, T Masszi, MT Petrucci, A Palumbo, L Rosiñol, A Nagler, KL Yong, ... Leukemia 31 (1), 107-114, 2017 | 144 | 2017 |
| Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients GJ Morgan, SA Schey, P Wu, M Srikanth, KJ Phekoo, M Jenner, ... British journal of haematology 137 (3), 268-269, 2007 | 142 | 2007 |
| Deletions of CDKN2C in multiple myeloma: biological and clinical implications PE Leone, BA Walker, MW Jenner, L Chiecchio, GP Dagrada, ... Clinical Cancer Research 14 (19), 6033-6041, 2008 | 138 | 2008 |
| Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma … G Cook, AJ Ashcroft, G Pratt, R Popat, K Ramasamy, M Kaiser, M Jenner, ... British journal of haematology 190 (2), e83, 2020 | 120 | 2020 |
| The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD) FE Davies, P Wu, M Jenner, M Srikanth, R Saso, GJ Morgan Haematologica 92 (8), 1149-1150, 2007 | 108 | 2007 |
| Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial JR Jones, DA Cairns, WM Gregory, C Collett, C Pawlyn, R Sigsworth, ... Blood cancer journal 6 (12), e506-e506, 2016 | 95 | 2016 |
| The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial C Pawlyn, D Cairns, M Kaiser, A Striha, J Jones, V Shah, M Jenner, ... Leukemia 34 (2), 604-612, 2020 | 89 | 2020 |
| Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials CA Bradbury, Z Craig, G Cook, C Pawlyn, DA Cairns, A Hockaday, ... Blood, The Journal of the American Society of Hematology 136 (9), 1091-1104, 2020 | 83 | 2020 |
| Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) CO Landgren, A Chari, YC Cohen, A Spencer, P Voorhees, JA Estell, ... Leukemia 34 (7), 1840-1852, 2020 | 82 | 2020 |
| The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study SA Schey, GJ Morgan, K Ramasamy, B Hazel, D Ladon, S Corderoy, ... British journal of haematology 150 (3), 326-333, 2010 | 77 | 2010 |
| Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study. GJ Morgan, FE Davies, RG Owen, AC Rawstron, S Bell, K Cocks, ... Blood, The Journal of the American Society of Hematology 110 (11), 3593-3593, 2007 | 70 | 2007 |
Gareth MorganNYUVerified email at nyulangone.org
